A Phase Ⅲ, Randomized Controlled Study to Evaluate the Efficacy and Safety of the Combination of Nab-paclitaxel and Gemcitabine Versus mFOLFIRINOX in Treating Patients With Borderline Reseactable and Locally Advanced Pancreatic Cancer

NCT04617821 Phase 3 UNKNOWN

This is a prospective, single-center, randomized, controlled phase Ⅲ study.

Details

Lead sponsor	Fudan University
Phase	Phase 3
Status	UNKNOWN
Enrolment	300
Start date	2021-09-01
Completion	2024-09

Conditions

• Borderline Resectable Pancreatic Cancer
• Locally Advanced Pancreatic Adenocarcinoma

Interventions

• Nab paclitaxel plus gemcitabine
• mFOLFIRINOX

Primary outcomes

• overall survival — from randomization to death, up to 36 months
  To evaluate the overall survival of patients with borderline resectable and locally advanced pancreatic cancer after treated neoadjuvant chemotherapy

Countries

China